A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol-Reference-Cited by-同舟云学术

A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol

Published:2018-06-03 Issue:5 Volume:122 Page:783-793
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Hofman Michael S.¹²^ORCID,Murphy Declan G.¹²^ORCID,Williams Scott G.¹²,Nzenza Tatenda¹²³^ORCID,Herschtal Alan⁴,Lourenco Richard De Abreu⁵,Bailey Dale L.⁶,Budd Ray⁷,Hicks Rodney J.¹²,Francis Roslyn J.⁸⁹,Lawrentschuk Nathan¹²³^ORCID

Affiliation:

1. Genitourinary Oncology Tumour Multidisciplinary Team; Departments of Cancer Imaging; Cancer Surgery and Radiation Oncology; Peter MacCallum Cancer Centre; Melbourne Vic. Australia

2. Sir Peter MacCallum Department of Oncology; University of Melbourne; Parkville Vic. Australia

3. Olivia Newton John Cancer Research Institute; Austin Health; Melbourne Vic. Australia

4. Centre for Biostatistics and Clinical Trials (BaCT); Peter MacCallum Cancer Centre; Melbourne Vic. Australia

5. Centre for Health Economics Research and Evaluation; University of Technology Sydney; Sydney NSW Australia

6. Nuclear Medicine; Royal North Shore Hospital; St Leonards NSW Australia

7. Medical Physics; Peter MacCallum Cancer Centre; Melbourne Vic. Australia

8. Nuclear Medicine; Sir Charles Gairdner Hospital; Perth Australia

9. Scientific Committee Chair; Australasian Radiopharmaceutical Trials Network (ARTnet); Australia

Funder

Prostate Cancer Foundation of Australia

Movember Australia

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.14374/fullpdf

Reference43 articles.

1. Guideline of guidelines: imaging of localized prostate cancer;Wollin;BJU Int,2015

2. [(18)F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients;Cimitan;Eur J Nucl Med Mol Imaging,2006

3. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer;Husarik;Eur J Nucl Med Mol Imaging,2008

4. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers;DeGrado;J Nucl Med,2001

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases;Seminars in Nuclear Medicine;2024-01

2. Evaluation of Real-World Efficiency of 177Lu-PSMA Radioligand Therapy of Metastatic Prostate Cancer;Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum;2024

3. Novel signatures of prostate cancer progression and therapeutic resistance;Expert Opinion on Therapeutic Targets;2023-12-02

4. Cost analysis of next-generation imaging in high-risk prostate cancer staging;Actas Urológicas Españolas (English Edition);2023-12

5. Análisis de coste de pruebas de nueva generación en estadificación de pacientes con cáncer de próstata de alto riesgo;Actas Urológicas Españolas;2023-11